KRAS and colorectal carcinoma: Similar results were obtained in other patient-derived CRC organoids that harbor a KRAS mutation (Figure 9—figure supplement 1) or, alternatively, with different combinations of inhibitors targeting the EGFR-RAS-ERK pathway (Figure 9—figure supplement 2).